Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vosoritide Phase 2 Dose-Escalation in Achondroplasia
NCT02055157Phase 2Completed
- Sponsor
- BioMarin Pharmaceutical
- Start
- Jan 2014
- Primary completion
- Oct 2017
- Modality
- Peptides
- Countries
- 4
01
Overview
A Phase 2 trial of vosoritide in achondroplasia (ACH), sponsored by BioMarin Pharmaceutical. Started Jan 2014; status: completed.
02
Drugs
vosoritide
03
Conditions
achondroplasia (ACH)
Beyond the preview
Go deeper on NCT02055157.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02055157.